Palisade Bio Inc
PALI
Get informed when a big investor buys or sells
+ FollowMarket Cap$324.59M
Close$
$2.39
23.4% upside
Current Fair Value
23.4% upsideUndervalued by 23.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $324.59 Million |
|---|---|
| Enterprise Value | $191.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.3 |
| Beta | 1.54 |
| Outstanding Shares | 209,663,966 |
Return
| Return on Equity | -18.96% |
|---|---|
| Return on Assets | -18.12% |
| Return on Invested Capital | -20.81% |
Valuation & Multiples
| P/E Ratio | -16.23 |
|---|---|
| PEG | -4.91 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.22 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 263.50%▼ 1554.50% |
|---|---|
| Total Invested | $256.82M▼ 19.58% |
| Investors Holding | 95▲ 9.00% |
ESG Score
No data
About Palisade Bio Inc
7 employees
CEO: I. Richard Garr Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB114...